Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine
Data(s) |
01/01/2015
|
---|---|
Resumo |
Conventional anticancer therapies, such as chemo- and/or radio-therapy are often unable to completely eradicate cancers due to abnormal tumor microenvironment, as well as increased drug/radiation resistance. More effective therapeutic strategies for overcoming these obstacles are urgently in demand. Aptamers, as chemical antibodies that bind to targets with high affinity and specificity, are a promising new and novel agent for both cancer diagnostic and therapeutic applications. Aptamer-based cancer cell targeting facilitates the development of active targeting in which aptamer-mediated drug delivery could provide promising anticancer outcomes. This review is to update the current progress of aptamer-based cancer diagnosis and aptamer-mediated active targeting for cancer therapy in vivo, exploring the potential of this novel form of targeted cancer therapy. |
Identificador | |
Idioma(s) |
eng |
Publicador |
Ivyspring International |
Relação |
http://dro.deakin.edu.au/eserv/DU:30070168/xiang-nucleicacidaptamer-2015.pdf http://www.dx.doi.org/10.7150/thno.10202 |
Direitos |
2015, Ivyspring International |
Palavras-Chave | #active targeting #aptamer #cancer stem cell #cancer theranostic #cancer therapy #chemoresistance #Science & Technology #Life Sciences & Biomedicine #Medicine, Research & Experimental #Research & Experimental Medicine #CELL ADHESION MOLECULE #MESOPOROUS SILICA NANOPARTICLES #INTERSTITIAL FLUID PRESSURE #ENDOTHELIAL GROWTH-FACTOR #SPONTANEOUS ANIMAL TUMORS #OVARIAN-CARCINOMA CELLS #TARGETED DRUG-DELIVERY #STEM-CELLS #IN-VIVO #BREAST-CANCER |
Tipo |
Journal Article |